


*IPW*

Please Direct All Correspondence to Customer Number **20995**



### AMENDMENT / RESPONSE TRANSMITTAL

Applicant : Landes, et al.  
 App. No : 10/726,332  
 Filed : December 2, 2003  
 For : ANTIBODIES DIRECTED TO  
 PHOSPHOLIPASE A2 AND USES  
 THEREOF  
 Examiner : Vandervegt, F. P.  
 Art Unit : 1644

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 13, 2006

(Date)

*Mallary K. de Merlier*  
Mallary K. de Merlier, Reg. No. 51,609

**Mail Stop Amendment**  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

- (X) Response to Amendment and Response to Restriction Requirement in 5 pages.
- (X) Return prepaid postcard.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

*Mallary K. de Merlier*

Mallary K. de Merlier  
 Registration No. 51,609  
 Attorney of Record  
 Customer No. 20,995  
 (619) 235-8550

ABGENIX.072A

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gregory M. Landes, et al.  
Appl. No. : 10/726,332  
Filed : December 2, 2003  
For : ANTIBODIES DIRECTED TO  
PHOSPHOLIPASE A2 AND USES  
THEREOF  
Examiner : Francois P. Vandervegt  
Group Art Unit : 1644

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 13, 2006

(Date)

Mallary K. de Merlier, Reg. No. 51,609

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed on September 15, 2006, Applicants submit the following amendments and remarks. Applicants hereby elect to prosecute the claims of Group I, Claims 1-16 and 19, drawn to a human monoclonal antibody to phospholipase A2, classified in class 530, subclass 388.15. Additionally, Applicants further elect, SEQ ID NO: 27 and SEQ ID NO: 28, as the specific immunoglobulin heavy chain sequence and light chain sequence, respectively.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks** begin on page 5 of this paper.